JP4616971B2 - １−アザビシクロアルカン化合物およびその医薬用途 - Google Patents

１−アザビシクロアルカン化合物およびその医薬用途 Download PDF

Info

Publication number
JP4616971B2
JP4616971B2 JP2000217709A JP2000217709A JP4616971B2 JP 4616971 B2 JP4616971 B2 JP 4616971B2 JP 2000217709 A JP2000217709 A JP 2000217709A JP 2000217709 A JP2000217709 A JP 2000217709A JP 4616971 B2 JP4616971 B2 JP 4616971B2
Authority
JP
Japan
Prior art keywords
azabicyclo
octane
benzo
thiophen
nicotinic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000217709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002030084A5 (enExample
JP2002030084A (ja
Inventor
雅和 藤尾
謙二 橋本
二郎 片山
敦 沼田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to JP2000217709A priority Critical patent/JP4616971B2/ja
Publication of JP2002030084A publication Critical patent/JP2002030084A/ja
Publication of JP2002030084A5 publication Critical patent/JP2002030084A5/ja
Application granted granted Critical
Publication of JP4616971B2 publication Critical patent/JP4616971B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000217709A 2000-07-18 2000-07-18 １−アザビシクロアルカン化合物およびその医薬用途 Expired - Fee Related JP4616971B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000217709A JP4616971B2 (ja) 2000-07-18 2000-07-18 １−アザビシクロアルカン化合物およびその医薬用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000217709A JP4616971B2 (ja) 2000-07-18 2000-07-18 １−アザビシクロアルカン化合物およびその医薬用途

Publications (3)

Publication Number Publication Date
JP2002030084A JP2002030084A (ja) 2002-01-29
JP2002030084A5 JP2002030084A5 (enExample) 2010-07-08
JP4616971B2 true JP4616971B2 (ja) 2011-01-19

Family

ID=18712778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000217709A Expired - Fee Related JP4616971B2 (ja) 2000-07-18 2000-07-18 １−アザビシクロアルカン化合物およびその医薬用途

Country Status (1)

Country Link
JP (1) JP4616971B2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
EP1432707B1 (en) 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) * 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN1675204A (zh) * 2002-06-10 2005-09-28 拜耳医药保健股份公司 2－杂芳基甲酰胺
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
MXPA05001702A (es) * 2002-08-14 2005-04-19 Neurosearch As Derivados de quinuclidina novedosos y su uso.
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ES2462545T3 (es) 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
DE602004010299T2 (de) 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
JP2007538011A (ja) 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
BRPI0517494A (pt) 2004-12-22 2008-10-14 Memory Pharm Corp composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
FR2884822B1 (fr) * 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2008118742A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
CA2894860C (en) 2008-11-19 2018-11-06 Gerhard Koenig Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5967284A (ja) * 1982-07-13 1984-04-16 サンド・アクチエンゲルシヤフト インドリルカルボン酸ピペリジルエステル誘導体
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
JP4163263B2 (ja) * 1995-04-06 2008-10-08 矢崎総業株式会社 防水コネクタ

Also Published As

Publication number Publication date
JP2002030084A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
JP2002030084A (ja) １−アザビシクロアルカン化合物およびその医薬用途
TWI417100B (zh) 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2001021615A1 (fr) Dérivés de benzimidazole
JP6968899B2 (ja) 向精神薬およびその使用
JPWO2009022731A1 (ja) Ｐ２ｘ４受容体拮抗剤
KR20060095865A (ko) 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
WO2001066546A1 (en) Spiro compounds, process for preparing the same and use thereof as drugs
JP2001512727A (ja) ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
JPWO2018021447A1 (ja) ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
DE69736890T2 (de) Kondensierte heterozyklische verbindungen und ihre pharmazeutische anwendung
JP5628937B2 (ja) ５−ｈｔ６受容体リガンドとしてのスルホン化合物
JPH0747585B2 (ja) イソオキサゾール誘導体
US5834482A (en) Heterocyclic chemistry
SK9398A3 (en) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2- -methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
WO1988003136A1 (fr) Composes de piperazine et leur utilisation medicinale
WO2021149767A1 (ja) ヘテロ環誘導体
RU2175970C2 (ru) Производные пиперидинилметилоксазолидин-2-она, способ их получения и фармацевтическая композиция на их основе
JP2003081978A (ja) スピロ環式化合物およびその医薬用途
CN109689650A (zh) 取代的n-[2-(4-苯氧基哌啶-1-基)-2-(1,3-噻唑-5-基)乙基]苯甲酰胺和n-[2-(4-苄氧基哌啶-1-基)-2-(1,3-噻唑-5-基)乙基]苯甲酰胺衍生物p2x7受体拮抗剂
JPH10152470A (ja) ピペラジン化合物
KR20240042472A (ko) 무스카린성 수용체 4 길항제 및 사용 방법
US11447484B2 (en) Cyclic compound having dopamine D3 receptor antagonistic effect
US12319659B2 (en) Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof
JP3786983B2 (ja) ピロリジノン誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070608

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100430

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101019

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101025

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131029

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees